ALTERITY THERAPEUTICS LTD(ATH.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

ATH.AU ALTERITY THERAPEUTICS LTD

Not Yet Opened 03-11 16:12:00 AEDT

0.01

+0.00

+11.11%

High0.01	Low0.01	Vol29.06M
Open0.01	D1 Closing0.01	Amplitude11.11%
Mkt Cap66.57M	Tradable Cap48.98M	Total Shares6.66B
T/O281.14K	T/O Rate0.59%	Tradable Shares4.90B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.01,"timestamp":1741669920000,"preClose":0.009,"halted":0,"volume":29056590,"delay":0,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":4897771134,"shares":6656849000,"eps":-0.003967,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"03-11 16:12:00 AEDT","open":0.01,"high":0.01,"low":0.009,"amount":281143,"amplitude":0.111111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.003967,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1741734000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.009,"openAndCloseTimeList":[[1741647600000,1741669200000]],"volumeRatio":3.0353763549448796,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/ATH.AU","defaultTab":"news","newsList":[{"id":"2514336316","title":"BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514336316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514336316?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 09:11","pubTimestamp":1740705070,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 MillionFeb 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX:HY NET LOSS AFTER TAX ATTRIBUTABLE A$7.2 MILLIONFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2514363131","title":"Alterity Therapeutics - Hy Net Loss After Tax Attributable a$7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514363131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514363131?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 09:10","pubTimestamp":1740705046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2513792579","title":"Alterity Therapeutics Ltd-Proposed Issue of Securities - Ath","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792579?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 13:07","pubTimestamp":1740373635,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUE28YFHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510938703","title":"Celebrity meme coins plunge 78% amid market shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2510938703","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510938703?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 09:02","pubTimestamp":1739322170,"startTime":"0","endTime":"0","summary":"Celebrity-endorsed meme coins have experienced significant downturns, plunging an average of 78% from their all-time highs .According to data from Messari, tokens like MOTHER , DADDY , TRUMP , MELANIA , and JAILSTOOL  have all decreased after reaching peak valuations.MOTHER, associated with Iggy Azalea, reached an all-time high of $0.2306 shortly after its launch in June 2024 but has since plummeted 96% to $0.00892.Despite this, recent market activity saw its price rise about 11% to $0.009067, with a trading volume of $4.2 million.Early buyers once held $45 million in unrealised profits, but DADDY has struggled to regain momentum, with its best post-ATH performance being a brief run past $0.16 last October.TRUMP, which briefly reaches over meme coin stalwarts like PEPE  and SHIB , is down 77.5% from its peak, while MELANIA has tumbled 88.7% from its $13.05 ATH.JAILSTOOL, promoted by Dave Portnoy, plummeted 83.3% from its ATH of $0.2179 on February 9, hitting an all-time low of $0.025 a","market":null,"thumbnail":"https://images.grafa.com/grafa/media-cryptocurrencies-celebrity-meme-coins-plunge-78--amid-market-shift-371110-638749189707891697.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-cryptocurrencies-celebrity-meme-coins-plunge-78--amid-market-shift-371110-638749189707891697.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/cryptocurrencies-celebrity-meme-coins-plunge-78--amid-market-shift-371110?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APT.USD.HKCC","TON.USD.CC","ATH.AU","TON.USD.HKCC","BK7067","APT.USD.CC"],"gpt_icon":0},{"id":"2510826250","title":"Alterity Therapeutics Raises AU$40 Million via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510826250","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510826250?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 13:05","pubTimestamp":1739250305,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ASX:ATH) is set to raise AU$40 million via a two-tranche placement at AU$0.011 apiece, according to a Monday Australian bourse filing.The first tranche of the placement is to ra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","ATH.AU","BK4139"],"gpt_icon":0},{"id":"2510560738","title":"Alterity Therapeutics Raises a$40.0 Million in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510560738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510560738?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LZFT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2510395859","title":"Alterity Therapeutics Ltd - Proceeds to Fund Ongoing Clinical Development for Ath434","url":"https://stock-news.laohu8.com/highlight/detail?id=2510395859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510395859?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LZFT2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2510705380","title":"BUZZ-Australia's Alterity Therapeutics falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510705380","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510705380?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 10:05","pubTimestamp":1739153104,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Alterity Therapeutics falls on discounted placement** Shares of Australia's Alterity Therapeutics ATH.AX fall as much as 8.3% to A$0.011, on track for a third consecutive session of decline** Stock hits its lowest level since Jan. 31** Biotechnology co raises A$40.0 mln  in a placement at an issue price of A$0.011 per share** Issue price represents a discount of 8.3% to stock's last close** Co says funds will be used primarily to advance development of ATH434, a small molecule drug candidate for Parkinsonian disorders** Stock up 43.8% this year, as of 0159 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL4N3P105B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510074336","title":"BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510074336","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510074336?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 09:17","pubTimestamp":1739150223,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSAFeb 10  - Alterity Therapeutics Ltd ATH.AX:ALTERITY RAISES A$40M TO ADVANCE ATH434 DEVELOPMENT IN MSAPLACEMENT WAS CONDUCTED AT A$0.011 PER SHAREFurther company coverage: ATH.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3OY2CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510607526","title":"Alterity raises $40M to propel neurodegenerative research","url":"https://stock-news.laohu8.com/highlight/detail?id=2510607526","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510607526?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 07:56","pubTimestamp":1739145400,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  has successfully raised A$40 million through a two-tranche placement to advance its ATH434 compound for treating neurodegenerative diseases like Parkinson’s.The capital raising, involving domestic and international institutional investors, was completed with strong support.The funds will primarily be used to accelerate the regulatory and development activities for ATH434, which has displayed significant slowing of clinical progression and a favourable safety profile in Multiple System Atrophy , a rare neurodegenerative disease.“We are grateful for the strong response from the investment community and are proud to welcome a number of leading domestic and international institutions as shareholders in support of Alterity as we advance our lead compound ATH434 for the treatment of neurodegenerative diseases,” said M.D and CEO of Alterity David Stamler.The placement was done at A$0.011 per share, with New Options attached.The first tranche is set to raise approximatel","market":null,"thumbnail":"https://images.grafa.com/grafa/media-business-news-alterity-raises--40m-to-propel-neurodegenerative-research-369157-638747422000247727.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-business-news-alterity-raises--40m-to-propel-neurodegenerative-research-369157-638747422000247727.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/business-news-alterity-raises--40m-to-propel-neurodegenerative-research-369157?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510736580","title":"Alterity Therapeutics - Alterity Raises a$40M to Advance Ath434 Development in MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510736580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510736580?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 07:23","pubTimestamp":1739143432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3OY2CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2510307396","title":"Alterity Therapeutics - Placement Was Conducted at a$0.011 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2510307396","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510307396?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 07:23","pubTimestamp":1739143432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3OY2CT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2509252535","title":"BRIEF-Alterity Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2509252535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509252535?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 05:55","pubTimestamp":1738792555,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Seeks Trading HaltFeb 6 (Reuters) - Alterity Therapeutics Ltd ATH.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  CAPITAL RAISINGFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2509252536","title":"Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on  Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2509252536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509252536?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 05:55","pubTimestamp":1738792530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2508163542","title":"Alterity Therapeutics secures $2.1M in US capital raise to accelerate ATH434 development","url":"https://stock-news.laohu8.com/highlight/detail?id=2508163542","media":"Grafa","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508163542?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 09:47","pubTimestamp":1738547251,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics , a biotechnology company focused on neurodegenerative disease treatments, has announced its success in raising capital in the US to accelerate the development of its lead candidate, ATH434.The additional funding follows positive topline results from the Phase 2 trial of ATH434-201 in multiple system atrophy , which were reported on Jan. 30.Moreover, the company expects to receive an estimated $5.7 million in rebates from the Australian Taxation Office in the first quarter of 2025 under the Australian Government's Research and Development Tax Incentive Scheme.Combined, the financial gains are intended to advance Alterity's clinical and regulatory efforts and accelerate the business development of ATH434.\"These funds will enable us to expand our clinical activities and pursue regulatory and business development opportunities,\" said David Stamler, CEO of Alterity Therapeutics.Alterity Therapeutics continues its commitment to addressing neurodegenerative diseases, wi","market":null,"thumbnail":"https://images.grafa.com/grafa/media-health-alterity-therapeutics-secures--2-1m-in-us-capital-raise-to-accelerate-ath434-development-363748-638741440519235300.jpeg","type":0,"news_type":0,"thumbnails":["https://images.grafa.com/grafa/media-health-alterity-therapeutics-secures--2-1m-in-us-capital-raise-to-accelerate-ath434-development-363748-638741440519235300.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://grafa.com/news/health-alterity-therapeutics-secures--2-1m-in-us-capital-raise-to-accelerate-ath434-development-363748?referralcode=A314DFDBE96C354756A893C6E3E02493","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XKO.AU","XJO.AU","ATH.AU","XAO.AU","BK7067"],"gpt_icon":0},{"id":"2508616891","title":"BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2508616891","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508616891?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 09:31","pubTimestamp":1738546295,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market FacilityFeb 3 (Reuters) - Alterity Therapeutics Ltd ATH.AX:RAISES A$2.13M VIA ITS AT-THE-MARKET FACILITYFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OS06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2508157992","title":"Alterity Therapeutics Raises About AU$2.1 Million Via US Facility; Shares Soar 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508157992","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508157992?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 08:36","pubTimestamp":1738543005,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  raised about AU$2.1 million capital in the US via an at-the-market facility, according to a Monday Australian filing.The company received the opportunity to raise the capital based on positive topline results from the phase two trial in multiple system atrophy for its ATH434 drug candidate, the filing said.ATH434 is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, it added.The company also expects to receive about AU$5.7 million in rebates from the Australian Taxation Office under the government's Research and Development Tax Incentive scheme.The proceeds will allow it to advance its clinical and regulatory activities.The firm's shares soared almost 17% in early trading on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","LENZ","BK7067","BK4139","ATH.AU","XJO.AU"],"gpt_icon":0},{"id":"2508513031","title":"Alterity Therapeutics -  Raises a$2.13M via Its at-the-Market Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2508513031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508513031?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 06:55","pubTimestamp":1738536920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2507604350","title":"Alterity Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2507604350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507604350?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 07:00","pubTimestamp":1738278000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATHE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 18:00 ET (23:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHE","ATH.AU","LENZ"],"gpt_icon":0},{"id":"2507609958","title":"Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2507609958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507609958?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 05:58","pubTimestamp":1738274326,"startTime":"0","endTime":"0","summary":"The most you can lose on any stock  is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Alterity Therapeutics Limited  share price had more than doubled in just one year - up 260%. Shareholders are also celebrating an even better 500% rise, over the last three months. In contrast, the longer term returns are negative, since the share price is 14% lower than it was three years ago.Since the stock has added AU$48m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.We think companies that have neither significant revenues nor profits are pretty high risk. You should be aware that the company needed to issue more shares recently so that it could raise enough money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-asx-ath-shareholder-215846964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ATHE","ATH.AU","BK4139","ATH","BK4162","BK7067","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alteritytherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1111},{"period":"1month","weight":-0.1667},{"period":"3month","weight":1},{"period":"6month","weight":2.3333},{"period":"1year","weight":1.5},{"period":"ytd","weight":0.25}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":0.0371},{"period":"3month","weight":0.08},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.2321},{"period":"ytd","weight":0.0913}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment of Parkinson's disease and other movement disorders. It is also developing PBT2 for patients with Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.36,"avgChangeRate":-0.042752},{"month":2,"riseRate":0.36,"avgChangeRate":-0.006908},{"month":3,"riseRate":0.4,"avgChangeRate":-0.015545},{"month":4,"riseRate":0.36,"avgChangeRate":-0.044012},{"month":5,"riseRate":0.4,"avgChangeRate":-0.009852},{"month":6,"riseRate":0.64,"avgChangeRate":0.126968},{"month":7,"riseRate":0.4,"avgChangeRate":0.063613},{"month":8,"riseRate":0.36,"avgChangeRate":-0.013959},{"month":9,"riseRate":0.24,"avgChangeRate":-0.050664},{"month":10,"riseRate":0.32,"avgChangeRate":-0.030082},{"month":11,"riseRate":0.52,"avgChangeRate":0.117279},{"month":12,"riseRate":0.48,"avgChangeRate":0.048644}],"exchange":"ASX","name":"ALTERITY THERAPEUTICS LTD","nameEN":"ALTERITY THERAPEUTICS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.6","shortVersion":"4.31.6","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALTERITY THERAPEUTICS LTD(ATH.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ALTERITY THERAPEUTICS LTD(ATH.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ALTERITY THERAPEUTICS LTD,ATH.AU,ALTERITY THERAPEUTICS LTD股票,ALTERITY THERAPEUTICS LTD股票老虎,ALTERITY THERAPEUTICS LTD股票老虎国际,ALTERITY THERAPEUTICS LTD行情,ALTERITY THERAPEUTICS LTD股票行情,ALTERITY THERAPEUTICS LTD股价,ALTERITY THERAPEUTICS LTD股市,ALTERITY THERAPEUTICS LTD股票价格,ALTERITY THERAPEUTICS LTD股票交易,ALTERITY THERAPEUTICS LTD股票购买,ALTERITY THERAPEUTICS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALTERITY THERAPEUTICS LTD(ATH.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ALTERITY THERAPEUTICS LTD(ATH.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction